PROMIS NEUROSCIENCES’ DATA FOR ALZHEIMER’S DISEASE CLINICAL CANDIDATE PMN310 PUBLISHED IN SCIENTIFIC REPORTS

TORONTO, Ontario and CAMBRIDGE, Mass. —July 9, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced that supporting data for PMN310, its lead antibody candidate for Alzheimer’s disease (AD), have been published in Scientific Reports, a journal of the Nature Research family. The open-access study is available on the Scientific Reports website  using the following direct link: https://rdcu.be/bJeLB MORE>>